<DOC>
	<DOCNO>NCT02726867</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety levetiracetam , lacosamide ketamine treatment refractory status epilepticus . This randomized , open-label , four-arm pilot study compare time cessation refractory status epilepticus , determine continuous EEG monitoring , patient refractory status epilepticus . Patients status epilepticus treat standard dose lorazepam ( midazolam ) ≥ 1000 mg phenytoin document level ≥20 mg/ml continue clinical status epilepticus ≥1-24 hour phenytoin load receive intravenously ( i.v . ) either 4000 mg levetiracetam , 600 mg lacosamide ( Group B ) , 2.5 mg/kg ketamine phenobarbital 15 mg/kg phenobarbital ( Group D )</brief_summary>
	<brief_title>Levetiracetam , Lacosamide Ketamine Adjunctive Treatment Refractory Status Epilepticus</brief_title>
	<detailed_description>40 18-70 year old men woman refractory status epilepticus , define status epilepticus continue &gt; 1 hour completion standard treatment lorazepam ( midazolam ) i.v . phenytoin ( fos-phenytoin ) , enrol . Participants randomize four treatment arm , levetiracetam 4000 ( Group A , n=10 ) , lacosamide 600 mg ( Group B , n=10 ) , ketamine 2.5 mg/kg ( group C , n=10 ) , phenobarbital 15 mg/kg ( Group D , n=10 ) 1:1:1:1 ratio . Baseline evaluation include continuous EEG , phenytoin level prior study intervention , CBC , CMP , serum Ca , Po4 Mg . Treatment consist levetiracetam 4000 mg i.v . 10 minute , lacosamide 600 mg i.v . 10 minute , ketamine 2.5 mg/kg 10 minute , phenobarbital 15 mg/kg mg i.v . 100 mg/minute rate . Participants evaluate ongoing physical examination continuous EEG monitoring . Continuous EEG monitoring start initiation study treatment , documentation electrographic status epilepticus . It continue throughout treatment period . Subjects observed 1 hour clinically continuous EEG monitoring cessation SE . Participants status epilepticus stop within 60 minute completion study treatment continue receive phenytoin ( 150 mg i.v . q 12 hour , standard dose ) study medication ( levetiracetam 1500 mg i.v . q 12 hourly , lacosamide 300 mg q 12 hourly , ketamine 50 mg qid ( vs. 40 mcg/kg/min i.v . infusion , clinically applicable , phenobarbital 90 mg i.v . q 12 hourly ) . Continuous EEG monitoring continue 72 hour monitor relapse status epilepticus . Participants status epilepticus fail stop within 60 minute completion study treatment ( `` non-responders '' ) undergo standard treatment medically-induced coma , intubation/ventilation i.v . midazolam propofol treatment dose titrate EEG effect `` burst suppression '' suppression background activity . All patient , responder non-responders alike , continue treatment phenytoin i.v. , 150 mg q 12 hourly , conscious patient , 300 mg p.o . qhs 72 hour completion study treatment . In patient require medical coma study treatment ( non-responders ) , medical coma discontinue 48 hour . All participant continue monitor continuous EEG 72 hour completion study treatment . If status epilepticus return time , medical coma re-instituted patient treat accord standard clinical care prolong SE</detailed_description>
	<mesh_term>Status Epilepticus</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Phenobarbital</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Etiracetam</mesh_term>
	<mesh_term>Piracetam</mesh_term>
	<criteria>1 . Age 1870 2 . Ability willingness surrogate sign informed consent form . 3 . Clinically electrographically document ongoing SE last ≥1 hour ≤24 hour 1 . Creatinine &gt; 2.5 mg/dl 2 . Any systemic illness unstable medical condition might pose additional risk , include : cardiac , metabolic endocrine disturbance , renal liver disease 3 . Active drug alcohol dependence factor , opinion site investigator would interfere adherence study requirement 4 . Pregnancy 5 . Inability unwillingness subject legal surrogate give write informed consent 6 . Known allergy study drug 7 . Hypo hyperglycemia cause SE</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>refractory status epilepticus</keyword>
	<keyword>levetiracetam</keyword>
	<keyword>lacosamide</keyword>
	<keyword>ketamine</keyword>
</DOC>